Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be944a7839fc8cabe752928d03dafaa4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01afbe89859dcd8d2117a916bd177d90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1fd654176241a733f7e89b922dedc719 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc1edbafdeddd4e7b9b1093227930122 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20022 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
filingDate |
2008-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2013-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4cbf55ec3fb179af4de0353613dd341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38186aa7223a74cc4c3c4dfc9db34dc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9316dfeba644c55604fd2207677e8449 |
publicationDate |
2013-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8420103-B2 |
titleOfInvention |
Papillomavirus vaccines |
abstract |
A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3′ portion of the first nucleotide which in the natural content is 100% identical to the 5′ portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11012555-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11012556-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019273820-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019158655-A1 |
priorityDate |
2007-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |